FDA Requests $7.2 Billion for Fiscal Year 2025

The U.S. Food and Drug Administration announced on Monday that it is seeking $7.2 billion for fiscal year 2025 to modernize the agency and its operations.

The budget proposal includes an increase of $495 million — or 7.4% above the fiscal year 2023 funding level.

“Our request for critical investments will help us address our most urgent priorities, strengthen our public health capacity, advance IT capabilities, and improve agency-wide infrastructure. The budget will also support the FDA’s ability to prepare for, build resilience to, and respond to shortages, support the implementation of expanded cosmetics regulation, and protect and promote a safe, nutritious U.S. food supply,” FDA Commissioner Robert M. Califf, M.D. said in a statement.

The FDA’s request includes $15 million to enhance food safety and nutrition. Funds will be used to invest in necessary tools and processes to strengthen root-cause investigations of foodborne illness, allowing for better prevention or mitigation.

Additionally, funding would help to address the enormous public health burden of diet-related chronic diseases, including obesity, type 2 diabetes, and hypertension.

The FDA seeks $12.3 million to support supply chain resiliency. In recent years, the United States saw an unprecedented shortage of medications, including cancer drug cisplatin and common antibiotics, partly due to gaps in supply chains.

The funding will allow the agency to hire additional investigators to carry out inspections associated with increased supply-chain disruptions. Developing and implementing modernized systems will help address the consequent human food and medical product shortages more quickly.

The FDA aims to strengthen its public health and mission-support capacity, as well as modernize its infrastructure and facilities. For instance, the agency requires 114.8 million to increase the wages of the public health employee workforce.

The request also includes $43.6 million to ensure optimal functioning of the FDA’s offices and labs. Funds will allow the agency to evaluate food safety and medical products and continue to expand laboratory operations aimed at reducing the flow of contaminated and illicit imported products.

The agency’s request also includes a package of legislative proposals, such as providing the FDA with additional authority to increase oversight of dietary supplements.

Currently, the FDA does not approve dietary supplements for any purpose because they are regulated as food rather than medications. The lack of oversight leaves patients vulnerable to dangerous and otherwise illegal products on the market.


Leave a reply

Your email will not be published. All fields are required.